A detailed history of Belpointe Asset Management LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Belpointe Asset Management LLC holds 39,770 shares of ABBV stock, worth $7.16 Million. This represents 0.53% of its overall portfolio holdings.

Number of Shares
39,770
Previous 37,708 5.47%
Holding current value
$7.16 Million
Previous $6.47 Million 21.43%
% of portfolio
0.53%
Previous 0.5%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$163.84 - $199.33 $337,838 - $411,018
2,062 Added 5.47%
39,770 $7.85 Million
Q2 2024

Aug 02, 2024

BUY
$154.79 - $180.76 $156,337 - $182,567
1,010 Added 2.75%
37,708 $6.47 Million
Q1 2024

May 08, 2024

BUY
$159.82 - $182.1 $343,293 - $391,150
2,148 Added 6.22%
36,698 $6.68 Million
Q4 2023

Feb 13, 2024

BUY
$137.6 - $154.97 $55,452 - $62,452
403 Added 1.18%
34,550 $5.35 Million
Q3 2023

Nov 15, 2023

BUY
$133.59 - $154.65 $129,715 - $150,165
971 Added 2.93%
34,147 $5.09 Million
Q2 2023

Aug 14, 2023

SELL
$132.51 - $164.9 $3.38 Million - $4.2 Million
-25,476 Reduced 43.44%
33,176 $4.47 Million
Q1 2023

May 15, 2023

SELL
$144.61 - $166.54 $342,147 - $394,033
-2,366 Reduced 3.88%
58,652 $9.35 Million
Q4 2022

Feb 08, 2023

BUY
$138.31 - $165.87 $664,856 - $797,337
4,807 Added 8.55%
61,018 $9.87 Million
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $1.4 Million - $1.6 Million
10,423 Added 22.76%
56,211 $7.54 Million
Q2 2022

Aug 02, 2022

SELL
$137.62 - $174.96 $1.36 Million - $1.73 Million
-9,900 Reduced 17.78%
45,788 $7.01 Million
Q1 2022

Apr 28, 2022

SELL
$131.98 - $163.75 $1.53 Million - $1.9 Million
-11,610 Reduced 17.25%
55,688 $9.03 Million
Q4 2021

Feb 15, 2022

BUY
$107.43 - $135.93 $158,351 - $200,360
1,474 Added 2.24%
67,298 $9.11 Million
Q3 2021

Nov 15, 2021

BUY
$106.4 - $120.78 $1.29 Million - $1.47 Million
12,164 Added 22.67%
65,824 $7.1 Million
Q2 2021

Aug 09, 2021

BUY
$105.21 - $117.21 $277,964 - $309,668
2,642 Added 5.18%
53,660 $6.04 Million
Q1 2021

May 14, 2021

SELL
$102.3 - $112.62 $669,758 - $737,323
-6,547 Reduced 11.37%
51,018 $5.52 Million
Q4 2020

Feb 16, 2021

BUY
$80.49 - $108.67 $253,141 - $341,767
3,145 Added 5.78%
57,565 $6.17 Million
Q3 2020

Nov 13, 2020

SELL
$85.91 - $100.83 $2.73 Million - $3.2 Million
-31,762 Reduced 50.22%
31,487 $2.4 Million
Q3 2020

Nov 13, 2020

BUY
$85.91 - $100.83 $1.97 Million - $2.31 Million
22,933 Added 72.83%
54,420 $4.77 Million
Q2 2020

Jul 20, 2020

BUY
$73.37 - $98.18 $2.33 Million - $3.12 Million
31,762 Added 100.87%
63,249 $6.21 Million
Q1 2020

Jul 20, 2020

SELL
$64.5 - $97.79 $119,196 - $180,715
-1,848 Reduced 5.54%
31,487 $2.4 Million
Q4 2019

Feb 18, 2020

BUY
$72.13 - $90.25 $432,130 - $540,687
5,991 Added 21.91%
33,335 $2.95 Million
Q3 2019

Jan 16, 2020

BUY
$62.98 - $75.72 $226,035 - $271,759
3,589 Added 15.11%
27,344 $2.07 Million
Q2 2019

Nov 22, 2019

SELL
$65.7 - $83.98 $39,222 - $50,136
-597 Reduced 2.45%
23,755 $0
Q1 2019

Jun 11, 2019

BUY
$77.14 - $90.79 $7,945 - $9,351
103 Added 0.42%
24,352 $1.96 Million
Q4 2018

Mar 06, 2019

BUY
$77.85 - $96.01 $338,024 - $416,875
4,342 Added 21.81%
24,249 $2.24 Million
Q3 2018

Nov 23, 2018

SELL
$88.91 - $98.84 $83,842 - $93,206
-943 Reduced 4.52%
19,907 $1.88 Million
Q2 2018

Aug 06, 2018

SELL
$89.78 - $106.23 $112,045 - $132,575
-1,248 Reduced 5.65%
20,850 $1.93 Million
Q1 2018

Aug 06, 2018

SELL
$92.01 - $123.21 $708,661 - $948,963
-7,702 Reduced 25.85%
22,098 $2.09 Million
Q4 2017

Feb 15, 2018

BUY
$89.56 - $98.21 $492,848 - $540,449
5,503 Added 22.65%
29,800 $2.88 Million
Q3 2017

Nov 16, 2017

BUY
$69.85 - $89.22 $1.7 Million - $2.17 Million
24,297
24,297 $2.16 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Belpointe Asset Management LLC Portfolio

Follow Belpointe Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Belpointe Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Belpointe Asset Management LLC with notifications on news.